These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Treatment of acute stroke]. Sztajzel R; Reichhart M; Michel P; Bogousslavsky J Rev Med Suisse; 2005 May; 1(18):1192-4, 1197-200. PubMed ID: 15977707 [TBL] [Abstract][Full Text] [Related]
3. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148 [TBL] [Abstract][Full Text] [Related]
4. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results. Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
6. GP IIb/IIIa blockade during peripheral artery interventions. Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207 [TBL] [Abstract][Full Text] [Related]
10. [Modification of clinical profile of stroke in atrial fibrillation patients. Effect of antithrombotic treatment]. García Escrivà A; López Hernández N; Hernández Lorido R; Oliver Navarrete C; Bustos S; Carneado Ruiz J; Gracia Fleta F; Moltó Jordá JM Rev Neurol; 2004 Mar 1-15; 38(5):401-5. PubMed ID: 15029514 [TBL] [Abstract][Full Text] [Related]
11. Role of antiplatelet agents in stroke. Mousa SA Curr Opin Investig Drugs; 2000 Dec; 1(4):464-7. PubMed ID: 11249700 [No Abstract] [Full Text] [Related]
12. Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non-ST elevation acute coronary syndrome: insights from the Sino-Global Registry of Acute Coronary Events. Zhang LJ; Chen YD; Song XT; Zhao FH; Lü SZ Chin Med J (Engl); 2009 Mar; 122(5):502-8. PubMed ID: 19323898 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI. Ferguson JJ; Wilson JM; Diez J Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162 [TBL] [Abstract][Full Text] [Related]
18. Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment. Bogousslavsky J; Paciaroni M; Gallai V Clin Exp Hypertens; 2002; 24(7-8):603-10. PubMed ID: 12450235 [TBL] [Abstract][Full Text] [Related]